A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Condition(s):Diffuse Large B-Cell LymphomaLast Updated:April 12, 2019Terminated
Hide Studies Not Open or Pending
Condition(s):Diffuse Large B-Cell LymphomaLast Updated:April 12, 2019Terminated
Condition(s):Diffuse Large B Cell LymphomaLast Updated:December 27, 2021Completed
Condition(s):Diffuse Large B-cell LymphomaLast Updated:March 16, 2016Withdrawn
Condition(s):Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaLast Updated:March 21, 2024Recruiting
Condition(s):Diffuse Large B-cell LymphomaLast Updated:October 27, 2014Completed
Condition(s):Diffuse Large B-cell LymphomaLast Updated:July 12, 2017Completed
Condition(s):Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS); Aggressive B-cell Lymphoma With Secondary Involvement of the CNSLast Updated:December 11, 2023Recruiting
Condition(s):Diffuse Large B Cell Lymphoma; Kaposi SarcomaLast Updated:December 7, 2017Withdrawn
Condition(s):Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell LymphomaLast Updated:March 26, 2024Recruiting
Condition(s):Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell LymphomaLast Updated:October 28, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.